← Back to Screener
Vanda Pharmaceuticals Inc. (VNDA)
Price$6.37
Value ScoreC
Growth ScoreC
Momentum ScoreC
Favorite Metrics
Price vs S&P 500 (26W)17.33%
Price vs S&P 500 (4W)-12.83%
VGM Score49.07
Market Capitalization$375.95M
All Metrics
Book Value / Share (Quarterly)$4.67
P/TBV (Annual)2.48x
Indicated Dividend (Annual)$0.00
Revenue Growth (3Y)-5.29%
Cash Flow / Share (Quarterly)$-2.28
Price vs S&P 500 (YTD)-37.80%
Gross Margin (TTM)94.18%
Net Profit Margin (TTM)-109.99%
EPS (TTM)$-4.05
10-Day Avg Trading Volume1.02M
EPS Excl Extra (TTM)$-4.05
Revenue Growth (5Y)-2.73%
EPS (Annual)$-3.74
ROI (Annual)-65.88%
Gross Margin (Annual)93.96%
Net Profit Margin (5Y Avg)-19.08%
Cash / Share (Quarterly)$3.36
Revenue Growth QoQ (YoY)3.35%
ROA (Last FY)-45.09%
Revenue Growth TTM (YoY)8.16%
EBITD / Share (TTM)$-2.59
ROE (5Y Avg)-12.53%
Operating Margin (TTM)-73.64%
Cash Flow / Share (Annual)$-1.87
P/B Ratio1.34x
P/B Ratio (Quarterly)1.45x
Net Income / Employee (Annual)$-413,600
EV / Revenue (TTM)1.51x
ROA (TTM)-44.60%
EV / EBITDA (TTM)257.32x
EPS Incl Extra (Annual)$-3.74
Current Ratio (Annual)2.39x
Quick Ratio (Quarterly)1.91x
3-Month Avg Trading Volume2.06M
52-Week Price Return46.92%
EV / Free Cash Flow (Annual)-31.46x
Revenue / Employee (TTM)$408,600
Tangible BV / Share (Quarterly)$2.75
P/S Ratio (Annual)1.74x
Asset Turnover (Annual)0.44x
52-Week High$9.94
Operating Margin (5Y Avg)-15.89%
EPS Excl Extra (Annual)$-3.74
CapEx CAGR (5Y)-11.13%
Tangible BV CAGR (5Y)-13.41%
26-Week Price Return33.26%
Quick Ratio (Annual)2.19x
13-Week Price Return-25.00%
Total Debt / Equity (Annual)0.02x
Current Ratio (Quarterly)2.16x
Enterprise Value$329.37M
Revenue / Share Growth (5Y)-4.00%
Asset Turnover (TTM)0.41x
Book Value / Share Growth (5Y)-7.68%
Revenue / Employee (Annual)$405,500
Inventory Turnover (Annual)7.29x
Pretax Margin (Annual)-64.16%
Cash / Share (Annual)$4.46
3-Month Return Std Dev69.33%
Gross Margin (5Y Avg)92.30%
Net Income / Employee (TTM)$-449,400
ROE (Last FY)-67.38%
EPS Basic Excl Extra (Annual)$-3.74
P/FCF (TTM)49.72x
Receivables Turnover (TTM)4.29x
EV / Free Cash Flow (TTM)-20.52x
Total Debt / Equity (Quarterly)0.03x
EPS Incl Extra (TTM)$-4.05
Receivables Turnover (Annual)4.25x
ROI (TTM)-60.43%
P/S Ratio (TTM)1.73x
Pretax Margin (5Y Avg)-10.44%
Revenue / Share (Annual)$3.67
Tangible BV / Share (Annual)$3.55
Price vs S&P 500 (52W)18.72%
Year-to-Date Return-26.87%
5-Day Price Return4.20%
EPS Normalized (Annual)$-3.74
ROA (5Y Avg)-8.20%
Net Profit Margin (Annual)-102.02%
Month-to-Date Return-9.15%
Cash Flow / Share (TTM)$0.25
EBITD / Share (Annual)$-2.45
Operating Margin (Annual)-69.95%
LT Debt / Equity (Annual)0.00x
ROI (5Y Avg)-12.23%
LT Debt / Equity (Quarterly)0.00x
EPS Basic Excl Extra (TTM)$-4.05
P/TBV (Quarterly)2.47x
P/B Ratio (Annual)1.59x
Inventory Turnover (TTM)7.00x
Pretax Margin (TTM)-68.74%
Book Value / Share (Annual)$5.54
Price vs S&P 500 (13W)-34.75%
Beta0.58x
P/FCF (Annual)30.27x
Revenue / Share (TTM)$3.66
ROE (TTM)-61.41%
52-Week Low$4.14
vGradeC
gGradeC
mGradeC
vgmGradeC
Show chart for
Earnings Surprise History
Q1 26-0.82est. -0.70
Analyst Recommendations
Feb 2026
Mar 2026
Apr 2026
May 2026
4.00
4.00
4.00
4.00
Industry Peers — Pharmaceuticals(550)
| Symbol | Value Score | Growth Score | Momentum Score | Price |
|---|---|---|---|---|
VNDAVanda Pharmaceuticals Inc. | C | C | C | $6.37 |
| LLYEli Lilly & Co. | D | B | B | $1082.20 |
| JNJJohnson & Johnson | C | C | C | $223.51 |
| ABBVABBVIE INC. | D | C | C | $212.93 |
| MRKMerck & Co., Inc. | C | C | C | $115.17 |
| NVSNovartis AG | C | C | C | $145.68 |
| AZNAstraZeneca PLC | D | B | C | $179.71 |
| NVONovo-Nordisk A/S | B | B | C | $44.07 |
| PFEPfizer Inc. | B | C | C | $25.63 |
| ABTAbbott Laboratories | C | C | D | $87.78 |
| TEVATeva Pharmaceutical Industries Limited American Depositary Shares | C | C | C | $34.64 |
About
Vanda Pharmaceuticals is a biopharmaceutical company developing therapies for neurology and psychiatry conditions with significant unmet medical needs. Its commercial portfolio includes HETLIOZ (for Non-24-Hour Sleep-Wake Disorder and Smith-Magenis Syndrome), Fanapt (schizophrenia), and PONVORY, with Fanapt generating the majority of revenue. The company operates primarily in the United States, with additional markets in Europe, Israel, and Canada, and maintains a pipeline of development-stage candidates.